RxDoctor Payments DataLook up a doctor →

Preetham Jetty, MD

Cardiovascular Disease · Anderson, INNPI 1962469510

Payments from drug & device makers

$420,305in general payments, 2019–2025

Across 539 payments — averaging $779.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$180K
  • Kowa Research Institute, Inc.$70K
  • Merck$42K
  • Esperion Therapeutics, Inc.$38K
  • Amarin Pharma, Inc.$30K
  • Astrazeneca UK Limited$25K
  • plus $37K from 36 others

What the payments were for

  • Speaking & faculty fees$49,34083%
  • Travel & lodging$1,3052%
  • Food & beverage$8,45514%
  • Education$620%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$420,305 in reported general payments places this provider in the 95th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$231,830
Medicare patients
1,596
Services billed
3,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,081$1,383,954
EntrestoSacubitril/Valsartan264$373,061
Repatha SureclickEvolocumab273$300,499
XareltoRivaroxaban191$257,463
VascepaIcosapent Ethyl236$219,301
MounjaroTirzepatide73$103,389
JardianceEmpagliflozin61$87,212
Praluent PenAlirocumab44$51,355
Icosapent Ethyl96$48,038
BrilintaTicagrelor67$44,883
NexlizetBempedoic Acid/Ezetimibe40$36,942
OzempicSemaglutide17$28,230
FarxigaDapagliflozin Propanediol21$25,550
Dabigatran EtexilateDabigatran Etexilate Mesylate97$24,066
Ranolazine ErRanolazine128$19,736

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23,630$1,383,9541,081 claims
NovartisEntresto$9,211$373,061264 claims
Johnson & JohnsonXarelto$434$257,463191 claims
Boehringer IngelheimJardiance$605$87,21261 claims
AstraZenecaBrilinta, Farxiga$179,525$70,43388 claims
Esperion Therapeutics, Inc.Nexlizet$38,129$36,94240 claims
Novo NordiskOzempic$245$28,23017 claims
Astellas Pharma US IncMyrbetriq$74$10,31014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Anderson

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →